(Q24201573)

1

0 references

John B Winer

2

0 references

Marinus Vermeulen

3

0 references

Rob de Haan

4

0 references

Ivo N van Schaik

Cochrane Database of Systematic Reviews

5

0 references

publication date

30 December 2013

0 references

published in

0 references

cites work

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

An "n of 1" trial of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Measuring quality of life in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

The Rochester Diabetic Neuropathy Study: Reassessment of tests and criteria for diagnosis and staged severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Incidence and prevalence of CIDP and the association of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Treatment approaches for Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Diagnostic value of sural nerve biopsy in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Future developments in the treatment of immune-mediated polyneuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Outcome measures in immune-mediated neuropathies: the need to standardize their use and to understand the clinimetric essentials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

In vitro effects of polyvalent immunoglobulin for intravenous use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

Interventions for preventing falls in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Ocular palsy preceding chronic relapsing polyneuropathy by several weeks

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIG in chronic inflammatory demyelinating polyneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021

Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001797.PUB3

7 January 2021